Evidence map›Paper›PMID 26750138›Full record

ArticlePathology oncology research : POR2016

The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas.

Jelena Jelicic, Milena Todorovic Balint, Maja Perunicic Jovanovic, Novica Boricic, Marjan Micev, Jelena Stojsic, Darko Antic, Bosko Andjelic, Jelena Bila, Bela Balint and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. OCT4 and Nestin Expression in the Microenvironment of Primary Central Nervous System Lymphomas.International journal of hematology-oncology and stem cell research · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Jelena JelicicClinic of Haematology, Clinical Centre of Serbia, 2, Koste Todorovica 2 str, 11000, Belgrade, Serbia.
Milena Todorovic BalintClinic of Haematology, Clinical Centre of Serbia, 2, Koste Todorovica 2 str, 11000, Belgrade, Serbia. bb.lena@gmail.com.
Maja Perunicic JovanovicDepartment of Histopathology, Clinical Centre of Serbia, Belgrade, Serbia.
Novica BoricicInstitute for Pathology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Marjan MicevDepartment of Histopathology, Clinical Centre of Serbia, Belgrade, Serbia.
Jelena StojsicDepartment of Histopathology, Clinical Centre of Serbia, Belgrade, Serbia.
Darko AnticClinic of Haematology, Clinical Centre of Serbia, 2, Koste Todorovica 2 str, 11000, Belgrade, Serbia.
Bosko AndjelicClinic of Haematology, Clinical Centre of Serbia, 2, Koste Todorovica 2 str, 11000, Belgrade, Serbia.
Jelena BilaClinic of Haematology, Clinical Centre of Serbia, 2, Koste Todorovica 2 str, 11000, Belgrade, Serbia.
Bela BalintInstitute for Transfusiology and Hemobiology, MMA, Belgrade, Serbia.
Sonja PavlovicInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
Biljana MihaljevicClinic of Haematology, Clinical Centre of Serbia, 2, Koste Todorovica 2 str, 11000, Belgrade, Serbia.
University of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prognostic significance of immune microenvironment has been emphasized using the most advanced analysis, with consecutive attempts to reveal prognostic impact of this findings. The aim of this study was to compare and define prognostic significance of clinical parameters, microvessel density (MVD) in tumour tissue and expression of CD44s as adhesive molecule on tumour cells in diffuse large B cell lymphoma-DLBCL, primary central nervous system DLBCL-CNS DLBCL and follicular lymphoma-FL. A total of 202 histopathological samples (115 DLBCL/65 FL/22 CNS DLBCL) were evaluated. Overall response (complete/partial remission) was achieved in 81.3 % DLBCL patients, 81.8 % primary CNS DLBCL and 92.3 % FL. Absolute lymphocyte count-ALC/Absolute monocyte count-AMC >2.6 in DLBCL and ALC/AMC ≥ 4.7 in FL were associated with better event-free survival (EFS) and overall survival (OS) (p < 0.05). In DLBCL, MVD > 42 blood vessels/0.36 mm(2) correlated with primary resistant disease (p < 0.0001), poorer EFS and OS (p = 0.014). High CD44s expression in FL correlated with inferior EFS and OS (p < 0.01). In DLBCL, multivariate Cox regression analysis showed that ALC/AMC was independent parameter that affected OS (HR 3.27, 95 % CI 1.51-7.09, p = 0.003) along with the NCCN-IPI (HR 1.39, 95 % CI 1.08-1.79, p = 0.01). Furthermore, in FL, ALC/AMC mostly influenced OS (HR 5.21, 95 % CI 1.17-23.21, p = 0.03), followed with the FLIPI (HR 3.98, 95 % CI 1.06-14.95, p = 0.041). In DLBCL and FL, ALC/AMC is simple and robust tool that is, with current prognostic scores, able to define long-term survival and identify patients with inferior outcome. The introduction of immunochemotherapy might altered the prognostic significance of microenvionmental biomarkers (MVD and CD44s).

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorDisease-Free SurvivalFemaleHumansHyaluronan ReceptorsLymphocyte CountLymphocytesLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMaleMicrovesselsMiddle AgedMonocytesBiomarkers, TumorCD44 protein, humanHyaluronan ReceptorsAdhesionAngiogenesisLymphocyte-to-monocyte countLymphoma

Identifiers

PMID26750138
OpenAlexW2234757576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.